

# "TEMPUS

## Tempus Announces Eight Abstracts Accepted For Presentation at the 2023 Society for Immunotherapy of Cancer Annual Meeting

November 1, 2023

Tempus, a leader in artificial intelligence and precision medicine, today announced eight abstracts were accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, which convenes in San Diego, California, from November 1-5, 2023.

"We continue to be a leader in the advancement of immunotherapy research, as evidenced by the abstracts we're presenting this year," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "We are making significant strides in advancing our own research initiatives while simultaneously supporting the therapeutic research efforts of our life science partners."

This year, highlights of Tempus' poster presentations include:

- **Poster Presentation (34): Association of a novel circulating tumor fraction DNA biomarker of treatment response monitoring and clinical outcomes in a real-world, diverse pan-cancer cohort treated with immunotherapy**
  - Session Date & Time: Saturday, Nov. 4, 2023; 9:00 a.m. – 8:30 p.m PST
  - Location: San Diego Convention Center; Exhibit Halls A and B1
  - Overview: This poster presents a novel approach for estimating circulating tumor DNA tumor fraction (ctDNA TF), ctDNA TF (denoted xF Monitor) utilizing diverse genomic events, and the association of changes in ctDNA TFs with ICI outcomes in a real-world pan-cancer cohort. xF Monitor is a novel serial quantitative ctDNA TF algorithm off the Tempus xF assay that has the potential to be used clinically as a predictive biomarker to stratify patients who may or may not be responding to ICI therapy.
- **Poster Presentation (158): Interrogating real world tumor-infiltrating T-cell repertoires to identify antigen enriched TCRs in a large pan-cancer clinical cohort**
  - Session Date & Time: Saturday, Nov. 4, 2023; 9:00 a.m. – 8:30 p.m PST
  - Location: San Diego Convention Center; Exhibit Halls A and B1
  - Overview: In this study, we analyzed a large, real-world, clinicogenomic database to identify public T-cell receptor (TCR) repertoires associated with HLA-specific neoantigens and viral epitopes. The database includes over 130k patients with TCR data covering a diverse landscape of HLA genotypes and tumor neoantigens. By incorporating routine TCR repertoire profiling into a high-volume clinical genomic sequencing program, we have developed a rich, multi-modal resource for studying complex tumor-immune interactions. This dataset is a valuable resource for TCR therapeutic discovery, and can help identify naturally occurring TCRs that may minimize on-target, off-tumor toxicity.

### About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit [tempus.com](https://tempus.com).